Sangamo Therapeutics discloses unauthorized professional payments in amended Chapter 11 report
SGMO•Sangamo Therapeutics reported an $11.17 million July net loss in an amended Chapter 11 operating report. Month-end cash was $16.91 million, and July borrowing under its Replacement DIP Facility totaled $18 million.
1. July operating report
Sangamo Therapeutics filed an amended Chapter 11 operating report on October 23, 2026, reporting an $11.17 million net loss for July. Cash totaled $16.91 million at month-end, compared with $14.38 million at the start of the month.
2. DIP facility borrowing
The company borrowed $18 million under its Replacement DIP Facility in July. Of that amount, $11.43 million satisfied outstanding obligations under the Initial DIP Facility, including fees.
